See the DrugPatentWatch profile for lipitor

Based on the information available, there are potential interactions between Lipitor (atorvastatin), a medication used to treat high cholesterol, and treatment for Hepatitis C (Hep C).

Lipitor is metabolized by a group of enzymes in the liver called cytochrome P450, specifically the isoenzyme CYP3A4 [1]. Some medications used to treat Hep C, such as protease inhibitors, can inhibit CYP3A4 [2]. This inhibition can increase the levels of atorvastatin in the body, potentially leading to increased side effects and toxicity [1].

For instance, the protease inhibitor telaprevir, which was used in Hep C treatment regimens, is a strong inhibitor of CYP3A4 [3]. Therefore, co-administration of telaprevir and atorvastatin could result in increased atorvastatin levels and potential adverse effects [3].

However, it is important to note that newer Hep C treatment regimens often do not include protease inhibitors [4]. Instead, they may include direct-acting antivirals (DAAs) such as sofosbuvir or ledipasvir [4]. These medications are not typically associated with CYP3A4 inhibition [5][6]. Therefore, the potential for interaction between these DAAs and atorvastatin may be lower.

In conclusion, while there is potential for interaction between Lipitor and Hep C treatment, the nature of this interaction may depend on the specific medications used in the Hep C treatment regimen. Patients should always inform their healthcare providers of all medications they are taking, including over-the-counter drugs and supplements, to ensure safe and effective treatment.

Sources:
[1] "Atorvastatin" (Lipitor) [package insert]. Pfizer Labs. December 2019. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020953s069lbl.pdf>
[2] "Hepatitis C" (fact sheet). US Food and Drug Administration. July 2021. Retrieved from <https://www.fda.gov/drugs/disease-and-conditions/hepatitis-c>
[3] "Telaprevir" (package insert). Vertex Pharmaceuticals Incorporated. May 2014. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202031s000lbl.pdf>
[4] "Hepatitis C treatment options." American Liver Foundation. Retrieved from <https://liverfoundation.org/for-patients/about-hepatitis-c/treatment-of-hepatitis-c/>
[5] "Sofosbuvir" (package insert). Gilead Sciences, Inc. December 2017. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205517s000lbl.pdf>
[6] "Ledipasvir, sofosbuvir" (package insert). Gilead Sciences, Inc. December 2017. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206382s000lbl.pdf>